Analysts’ Weekly Ratings Updates for Charles River Laboratories International (CRL)

Charles River Laboratories International (NYSE: CRL) has recently received a number of price target changes and ratings updates:

• 5/11/2026 – Charles River Laboratories International was downgraded by Weiss Ratings from “sell (d)” to “sell (e+)”.
• 5/8/2026 – Charles River Laboratories International was given a new $213.00 price target by Robert W. Baird.
• 5/8/2026 – Charles River Laboratories International had its “outperform” rating reaffirmed by Evercore Inc. They now have a $220.00 price target on the stock.
• 5/8/2026 – Charles River Laboratories International was given a new $192.00 price target by Mizuho.
• 5/8/2026 – Charles River Laboratories International had its price target raised by Barclays PLC from $210.00 to $220.00. They now have an “overweight” rating on the stock.
• 4/20/2026 – Charles River Laboratories International had its “sell (d)” rating reaffirmed by Weiss Ratings.
• 4/14/2026 – Charles River Laboratories International had its price target raised by Barclays PLC from $200.00 to $210.00. They now have an “overweight” rating on the stock.
• 4/14/2026 – Charles River Laboratories International is now covered by Royal Bank Of Canada. They set an “outperform” rating and a $215.00 price target on the stock.
• 4/14/2026 – Charles River Laboratories International is now covered by Royal Bank Of Canada. They set a “moderate buy” rating and a $215.00 price target on the stock.
• 4/13/2026 – Charles River Laboratories International had its price target lowered by JPMorgan Chase & Co. from $165.00 to $160.00. They now have a “neutral” rating on the stock.
• 4/8/2026 – Charles River Laboratories International had its “outperform” rating reaffirmed by Evercore Inc.

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.